{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix B: Karnofsky Performance Status (KPS) Scale', '50', 'Appendix C: Memorial Sloan Kettering Cancer Center (MSKCC) Criteria', '51', 'Appendix D: Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', '52', 'Appendix E: The European Organization for Research and Treatment of Cancer Quality of Life', 'Questionnaire (EORTO QLQ-C30 Version 3)', '57', 'Appendix F: FACT-Kidney Symptom Index - 15 (FKSI-15) Questionnaire', '59', 'Appendix G: The Perceived Stress Scale (PSS) Questionnaire', '60', 'Page 4 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'List of Abbreviations', 'AC - adenyl cyclase', 'AE - adverse event', 'ALP - alkaline phosphatase', 'ALT - alanine transaminase', 'ANA - antinuclear antibodies', 'ANOVA - analysis of variance', 'AP-1 - activator protein 1', 'APTT - activated partial thromboplastin time', 'AST - aspartate aminotransferase', 'AV - atrioventricular', 'BAD - BCL2-associated death protein', \"cAMP - cyclic 3'-5' adenosine monophosphate\", 'ccRCC - clear-cell renal cell carcinoma', 'CI - confidence Interval', 'COX - cyclooxygenase', 'CR - complete response', 'CRF - Case Report Form', 'CREB/ATF - cAMP response element binding protein/activating transcription factor', 'crRCC - chromophobe renal cell carcinoma', 'CSF-1R - colony stimulating factor 1 receptor', 'CT - computed tomography', 'CTLA-4 - cytotoxic T-lymphocyte-associated antigen 4', 'CYP - cytochrome P', 'D day', 'DCR - disease control rate', 'DRS - disease-related stress', 'E - epinephrine', 'ECG - electrocardiography', 'EGF - epidermal growth factor', 'ELISA - enzyme-linked immunosorbent assay', 'EMA - European Medical Agency', 'EMT - epithelial-mesenchymal transition', 'EORTO - European Organisation for Research and Treatment of Cancer', 'EPAC - exchange protein activated by adenylyl cyclase', 'EPO - erythropoietin', 'ERK - extracellular signal-regulated kinase', 'FAK - focal adhesion kinase', 'FDA - Food and Drug Administration', 'FGF - fibroblast growth factor', 'FGFR - fibroblast growth factor receptor', 'FKSI-15 - FACT-Kidney Symptom Index - 15', 'Page 5 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'FLT-3 - fms-related tyrosine kinase 3', 'GCP - Good Clinical Practice', 'HER-2 - human epidermal growth factor receptor 2', 'HGF - hepatocyte growth factor', 'HIF - hypoxia-inducible factor', 'HIV - human immunodeficiency virus', 'HLQoL - health related quality of life', 'HLRCC - hereditary leiomyomatosis and renal cell cancer', 'HR - hazard ratio', 'IFN-a - Interferon alpha', 'IH - infantile haemangioma', 'IL - interleukin', 'INR - international normalized ratio', 'IRB - Institutional Review Board', 'IV - intravenous', 'KIT - v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog', 'LMWH - low molecular weight heparin', 'MAPK - mitogen-activated protein kinase', 'MEK - mitogen-activated protein kinase kinase', 'MMP - matrix metalloproteinase', 'MRI - magnetic resonance imaging', 'MSKCC - Memorial Sloan-Kettering Cancer Center', 'mTOR - mammalian target of rapamycin', 'MU - million units', 'NA - not applicable', 'NE - norepinephrine', 'NFkB - nuclear factor kappa B', 'NK - natural killer', 'os - overall survival', 'PD - progressive disease', 'PD-1 - programmed death-1', 'PDGF - platelet-derived growth factor', 'PDGFR - platelet-derived growth factor receptor', 'PET - positron emission tomography', 'PFS - progression-free survival', 'PI3K - phosphoinositide 3-kinase', 'PKA - protein kinase A', 'PSS - Perceived Stress Scale', 'PR - partial response', 'pRCC - papillary enal cell carcinoma', 'QoL - quality of life', 'RANKL - receptor activator of nuclear factor kappa-B ligand', 'RCC - renal cell carcinoma', 'RECIST - Response Evaluation Criteria in Solid Tumors', 'Page 6 of 60']\n\n###\n\n", "completion": "END"}